AtaGenix Laboratories
AtaGenix Laboratories
AtaGenix offers diverse custom antibody discovery services to meet various research and industrial needs. Our expertise includes hybridoma sequencing, modified antibody development, rapid mouse monoclonal antibody generation, bispecific antibody development, small molecule antibody generation, phage display library screening, and the production of neutralizing/blocking and anti-idiotype antibodies.
Explore real-world yeast protein expression case studies from AtaGenix. Our Pichia pastoris and Saccharomyces cerevisiae platforms deliver high-yield recombinant proteins with proper folding and glycosylation — supporting enzyme production, diagnostic antigen development, and antibody screening applications.
A 2021 Small Methods study used dual phage display libraries — an overlapping spike peptide library for epitope mapping and a 8.7×10⁹ patient-derived ScFv library for antibody discovery — to identify three immunodominant RBM epitopes (S431–454, S470–486, S501–515) and isolate human neutralizing monoclonal antibodies from COVID-19 patients. S470–486 emerged as the key protective epitope (diagnostic AUC ~1.0; mouse immunization produced neutralizing antibodies). AtaGenix provided phage library construction, biopanning screening, and antibody expression services that enabled the 10⁹-scale discovery campaign. DOI: 10.1002/smtd.202100058.
Contact Us
+86-27-87001869
info@atagenix.com
Building C, R & D Building, No. 666, Shendun 4th Road, Donghu New Technology Development Zone, Wuhan
